Serge Bischoff

Rhenovia Pharma President & CEO, Co-founder

Dr. Serge Bischoff is co-founder, President and CEO of Rhenovia, a biotechnology SME, created in 2007, world leader in biosimulation of the Nervous System, incorporated in France and USA. He spent over 43 years in medical and pharmaceutical research in neurosciences. After his PhD period at the University P&M Curie, Paris, the Assistance Publique - Hôpitaux de Paris and INSERM (1969-75), Serge Bischoff spent most of his professional life in the large pharma industry (Synthélabo-Sanofi, Ciba-Geigy, Novartis). He was Head of various research programs for the search of new treatments of psychiatric (schizophrenia, depression), neurological (epilepsy, stroke) and neurodegenerative diseases (Alzheimer, Parkinson). Expert in neurobiochemistry and drug discovery, he contributed to bring several medication candidates in clinical development. Author of several patents and over hundred scientific publications and analysis articles, he is laureate of numerous awards including the Young Psychiatry Scientist Award by the Swiss Society of Psychiatry for basic research finding related to schizophrenia or the Leading Scientist Award by the Executive Management of Novartis, or with Rhenovia the French National Contest of Creation of Innovative Enterprises or very recently the World Contest of Innovation. He left Novartis in 2003 to dedicate his time to promote new approaches for drug discovery and especially the use of informatics tools, modeling & simulation to improve the search for better and less costly medications via the creation of a company which became Rhenovia Pharma. In parallel, he followed accelerated entrepreneurship trainings at the University of Basel, the Business Schools EM Lyon and Babson College, Boston.